Halozyme Therapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Halozyme Therapeutics sits in the top decile of US sponsors by registered trial count (#526 of 15,742 sponsors by registered trial count).
Halozyme Therapeutics: 31 sponsored US clinical trials, 1 recruiting.
Halozyme Therapeutics sponsors 31 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 27 completed. 9 of these trials are in Phase 3-4 (later-stage) and 22 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Risk Factors for or a Diagnosis of Osteoporosis, with 1 trials.
Top-decile sponsor footprint
Halozyme Therapeutics ranks in the top decile of sponsors by registered trial count (#526 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
27 of 30 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (90.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
31 total, page 1 of 1
52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism
NCT06689085
Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
NCT03267940
A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma
NCT02715804
A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors
NCT02563548
A Phase 1b Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Docetaxel in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic NSCLC
NCT02346370
A Study of Continuous Subcutaneous Insulin Infusion (CSII) Pump Function in Subjects With Type 1 Diabetes With Recombinant Human Hyaluronidase (rHuPH20)
NCT03662334
PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer
NCT01839487
CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)
NCT01848990
Phase 1 Safety, Tolerability and PK Study of Ondansetron and Hylenex Recombinant in Healthy Volunteers
NCT01572012
Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase
NCT01526733
Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer
NCT01453153
Randomized, Double-blind, Crossover, Pharmacokinetic (PK) and Glucodynamic (GD) Study of Continuous Subcutaneous Insulin Infusion (CSII) in Participants With Type 1 Diabetes Mellitus (T1DM)
NCT01275131
Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus
NCT01194258
Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus
NCT01194245
Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors
NCT01170897
A Pharmacokinetic and Glucodynamic Study of Subcutaneously Administered Insulin Analogs With rHuPH20 Compared to Insulin Analogs Alone
NCT00979875
Liquid Meal Study With Insulin Lispro With/Without Recombinant Human Hyaluronidase PH20 (rHuPH20) and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Participants With Type 2 Diabetes Mellitus (T2DM)
NCT00916357
Study of the Intradermal Injection of rHuPH20 or Placebo in Participants With Nickel Allergic Contact Dermatitis
NCT00928447
Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus
NCT00883558
Pharmacokinetic and Glucodynamic Crossover Study of Subcutaneously (SC) Administered Insulin Lispro + Recombinant Human Hyaluronidase (rHuPH20) and Regular Human Insulin + rHuPH20 Compared to Insulin Lispro Alone
NCT00862849
Safety Study of PEGPH20 Given to Patients With Advanced Solid Tumors
NCT00834704
Pharmacokinetic, Safety and Tolerability Study of SC Administered Bisphosphonate With rHuPH20 vs Bisphosphonate Alone
NCT00807963
Dose-Ranging, Pharmacokinetic (PK), Glucodynamic (GD), Safety and Tolerability Study of Subcutaneously (SC) Administered Humulin R and Humalog With or Without rHuPH20
NCT00803972
Study of Immediate Post-Operative Intravesical Instillation of Chemophase® in Patients With Superficial Bladder Cancer
NCT00782587
Phase II Pharmacokinetics Study of Humalog and Humulin-R With and Without rHuPH20 in Type 1 Diabetes Mellitus
NCT00774800
Subcutaneous Rehydration Compared to Intravenous Rehydration
NCT00773175
Study of Subcutaneous Hydration Enabled by Human Recombinant Hyaluronidase (Hylenex)
NCT00656370
Pharmacokinetic (PK), Pharmacodynamic (PD), and Safety Study of Subcutaneously Administered Humalog® With and Without Recombinant Human Hyaluronidase (rHuPH20)and Humulin-R® With and Without rHuPH20
NCT00705536
Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Participants With Superficial Bladder Cancer
NCT00318643
INFUSE Morphine Study
NCT00593281
A Phase IIIB Dose Comparison Study of Subcutaneous Hydration With and Without Human Recombinant Hyaluronidase (HYLENEX) in Volunteer Subjects
NCT00311519
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 15 |
| Phase 2 | 7 |
| Phase 3 | 3 |
| Phase 4 | 6 |
What is open in the Halozyme Therapeutics pipeline
1 recruiting of 31 indexed (3% open); 27 completed (87%).
Phase mix: 9 late (III/IV) vs 22 early (I/II) (early-phase heavy).
Top condition: Risk Factors for or a Diagnosis of Osteoporosis (1 trial), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Halozyme Therapeutics: open-pipeline peers nationwide
Peers matched on 31 registered trials and 3% open enrollment, not the therapeutic-area sidebar.
Halozyme Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 31 trials (± recruiting share)
- Children's Hospitals and Clinics of Minnesota · 31 trials · 10% recruiting
- Cook Group Incorporated · 31 trials · 0% recruiting
- Cytokinetics · 31 trials · 10% recruiting
- Insmed Incorporated · 31 trials · 6% recruiting
Sponsors near 3% open enrollment (± trial volume)
- New York State Psychiatric Institute · 3% recruiting · 364 trials
- Allina Health System · 3% recruiting · 32 trials
- CooperVision · 3% recruiting · 64 trials
- Masimo Corporation · 3% recruiting · 96 trials
Related
What to do with this Halozyme Therapeutics page
31 registered trials is a research-attention snapshot, not an endorsement of Halozyme Therapeutics or any single study.
- 1 of Halozyme Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Risk Factors for or a Diagnosis of Osteoporosis is the condition Halozyme Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Risk Factors for or a Diagnosis of Osteoporosis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Halozyme Therapeutics pipeline card: 31 registered trials from official public datasets.Report a data error.